PubRank

Tanja Cufer

Author PubWeight™ 50.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009 6.56
2 International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009 2.77
3 Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006 2.48
4 International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010 2.28
5 Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002 2.25
6 Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008 2.00
7 TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011 1.85
8 The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2008 1.68
9 Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 2005 1.48
10 International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013 1.31
11 Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011 1.30
12 Electrochemotherapy of chest wall breast cancer recurrence. Cancer Treat Rev 2012 1.27
13 Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008 1.19
14 Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol 2004 1.17
15 Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer 2006 1.13
16 The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2007 1.09
17 Barriers and challenges to global clinical cancer research. Oncologist 2013 1.01
18 Proteases and metastasis: clinical relevance nowadays? Curr Opin Oncol 2005 0.97
19 Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 2012 0.90
20 Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol 2012 0.89
21 Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2007 0.88
22 Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 2004 0.87
23 Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003 0.87
24 Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 2011 0.87
25 Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol Oncol 2008 0.84
26 Lung cancer stem cells: a biological and clinical perspective. Cell Oncol (Dordr) 2013 0.84
27 Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions. Radiol Oncol 2013 0.82
28 Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anticancer Drugs 2006 0.82
29 Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr 2010 0.82
30 High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res Treat 2009 0.81
31 Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs 2004 0.81
32 Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 2003 0.80
33 Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 2008 0.79
34 Estimation of renal function in lung cancer patients. Lung Cancer 2011 0.79
35 Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer 2013 0.79
36 Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications. J Cancer Res Ther 2013 0.79
37 Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study. J Thorac Oncol 2015 0.79
38 Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 2005 0.79
39 Current controversies in extended adjuvant endocrine therapy for early breast cancer. Curr Opin Oncol 2008 0.77
40 Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin Breast Cancer 2002 0.76
41 The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 2008 0.75